Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GAP3KO Malaria Vaccine Phase 1
NCT03168854Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jul 2017
- Primary completion
- Aug 2019
- Modality
- Gene Editing, Gene Silencing, Live Attenuated Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of GAP3KO in malaria (3 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Breakthrough peripheral parasitemia, Laboratory toxicities related to vaccination that are classified as Grade 3(Severe) and 4 more. Started Jul 2017; status: completed.
02
Drugs
GAP3KO
03
Conditions
malaria
Beyond the preview
Go deeper on NCT03168854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03168854.